Jihua Zhao, Dandan Niu, Zhuolin Jin, Jiaqi Liu, Dan Ni, Nokuthula Peace Mchunu, Ruyi Fan, Suren Singh, Zhengxiang Wang
{"title":"Engineered β-galactosidase catalyzes lactose to prebiotics in situ in raw milk.","authors":"Jihua Zhao, Dandan Niu, Zhuolin Jin, Jiaqi Liu, Dan Ni, Nokuthula Peace Mchunu, Ruyi Fan, Suren Singh, Zhengxiang Wang","doi":"10.1007/s10529-025-03601-8","DOIUrl":null,"url":null,"abstract":"<p><p>The enzymatic conversion of lactose to galactooligosaccharides (GOS) within raw milk offers a promising avenue for reducing lactose content while enhancing its prebiotic benefits. This process hinges on utilizing enzymes with high transglycosylation activity compatible with current milk processing methods. In the present studies, Bacillus circulans β-galactosidase (BglD) was identified as an effective enzyme, achieving a lactose conversion rate of 73.61% in milk. However, BglD's resistance to pasteurization underscored the need for enzyme modifications. Through molecular directed evolution, a mutant T473L/R484P was engineered. It exhibited improved catalytic performance at lower temperatures, with optimal activity at pH 6.5 and 55 °C. In contrary to the wild-type, mutant T473L/R484P exhibited reduced thermostability, and its activity diminished rapidly above 50 °C. Remarkably, in simulated dairy environments, mutant T473L/R484P converted over 78% to 82% of lactose at low temperatures (5 to 10 °C), reducing lactose to around 10.4 to13.0 g/L while generating approximately 30 to 34 g/L of GOS. These findings highlight the mutant's potential in producing low-lactose, GOS-enriched milk, and pave the way for innovative in situ lactose-to-GOS conversion processes in raw milk.</p>","PeriodicalId":8929,"journal":{"name":"Biotechnology Letters","volume":"47 4","pages":"66"},"PeriodicalIF":2.0000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Letters","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10529-025-03601-8","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The enzymatic conversion of lactose to galactooligosaccharides (GOS) within raw milk offers a promising avenue for reducing lactose content while enhancing its prebiotic benefits. This process hinges on utilizing enzymes with high transglycosylation activity compatible with current milk processing methods. In the present studies, Bacillus circulans β-galactosidase (BglD) was identified as an effective enzyme, achieving a lactose conversion rate of 73.61% in milk. However, BglD's resistance to pasteurization underscored the need for enzyme modifications. Through molecular directed evolution, a mutant T473L/R484P was engineered. It exhibited improved catalytic performance at lower temperatures, with optimal activity at pH 6.5 and 55 °C. In contrary to the wild-type, mutant T473L/R484P exhibited reduced thermostability, and its activity diminished rapidly above 50 °C. Remarkably, in simulated dairy environments, mutant T473L/R484P converted over 78% to 82% of lactose at low temperatures (5 to 10 °C), reducing lactose to around 10.4 to13.0 g/L while generating approximately 30 to 34 g/L of GOS. These findings highlight the mutant's potential in producing low-lactose, GOS-enriched milk, and pave the way for innovative in situ lactose-to-GOS conversion processes in raw milk.
期刊介绍:
Biotechnology Letters is the world’s leading rapid-publication primary journal dedicated to biotechnology as a whole – that is to topics relating to actual or potential applications of biological reactions affected by microbial, plant or animal cells and biocatalysts derived from them.
All relevant aspects of molecular biology, genetics and cell biochemistry, of process and reactor design, of pre- and post-treatment steps, and of manufacturing or service operations are therefore included.
Contributions from industrial and academic laboratories are equally welcome. We also welcome contributions covering biotechnological aspects of regenerative medicine and biomaterials and also cancer biotechnology. Criteria for the acceptance of papers relate to our aim of publishing useful and informative results that will be of value to other workers in related fields.
The emphasis is very much on novelty and immediacy in order to justify rapid publication of authors’ results. It should be noted, however, that we do not normally publish papers (but this is not absolute) that deal with unidentified consortia of microorganisms (e.g. as in activated sludge) as these results may not be easily reproducible in other laboratories.
Papers describing the isolation and identification of microorganisms are not regarded as appropriate but such information can be appended as supporting information to a paper. Papers dealing with simple process development are usually considered to lack sufficient novelty or interest to warrant publication.